

PERSONAL INFORMATION

Christos Reppas



Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Zografou, Greece

+30 210 7274678 +30 693 7179155

reppas@pharm.uoa.gr

Sex Male | Date of birth 29/01/1961 | Nationality Greece

WORK EXPERIENCE

2010 - Current	Professor in Pharmaceutics, Department of Pharmacy, National and Kapodistrian University of Athens (NKUA), Greece
2002 - 2010	Associate Professor in Drug Absorption, Department of Pharmacy, NKUA, Greece
1993-2002	Assistant Professor in Biopharmaceutics-Pharmacokinetics, Faculty of Pharmacy, NKUA, Greece
1989-1993	Lecturer in Biopharmaceutics – Pharmacokinetics, Faculty of Pharmacy, NKUA, Greece
1988-1990	Research Fellow in Pharmaceutics, College of Pharmacy, The University of Michigan, Michigan, USA

EDUCATION AND TRAINING

5/1998-10/1998	Visiting Professor Goethe University, Frankfurt/Main, Germany
11/1986-11/1987	Research Assistant in Clinical Pharmacokinetics during the Military Service NIMTS Hospital, Athens, Greece
1982 – 1986	PhD in Pharmaceutical Sciences (Specialty: Biopharmaceutics – Pharmacokinetics) https://www.didaktorika.gr/eadd/handle/10442/0184 Faculty of Pharmacy, NKUA, Greece
1/1984-5/1984	Visiting Scientist Chelsea College, University of London, UK.
1983	Registered Pharmacist Greece
1978 – 1982	Degree in Pharmacy Faculty of Pharmacy, NKUA, Greece
Mother tongue(s)	Greek

Other language(s)

English

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C2	C2	C2	C2	C2

Organisational / managerial skills

Experience in managing research and training activities acquired through the coordination of various EU and industry funded programs and acting as principal advisor of 14 completed Doctoral Theses.

Job-related skills

Designing and performing clinical studies in healthy adults

Driving licence

B

ADDITIONAL INFORMATION

Publications and citations

<https://scholar.google.com/citations?user=rjmwLWkAAAAJ&hl=en>

Projects

Participation

Dow Chemical Co., Midland, USA (1988 - 1989)

Influence of Methylcelluloses on flow rate, viscosity, and water flux in the gastrointestinal tract
US \$ 49999 (University of Michigan, College of Pharmacy)

Novartis, Switzerland, 2019-2020

Investigation of the usefulness of BioGIT in the comparison of the intraluminal performance of various products and doses of Novartis internal drug against existing in vivo data in adults.
49140 € | NKUA project number 56.90.16235

Novartis, Switzerland, 2019-2021

Evaluation of the impact of bacterial activity in the lower intestine on the clinical performance of LCZ696 based on data in optimized human fecal material. Biorelevant dissolution testing of LCZ modified products using the USP IV apparatus.
167640€ (NKUA project number 56.90.16304)

European Training Network, Marie Skłodowska-Curie actions

European Union's Horizon 2020 Research and Innovation Programme (2021-2024)

Drug Absorption in Geriatric Patients and Older People: a training network innovating drug development for the advanced age population, AGePOP, (www.agepop.eu)
906034€ (NKUA project number 70/3/16868)

Novartis, Switzerland, 2023-2024

On the usefulness of BioGIT in the evaluation of the intraluminal performance of different drug products and doses of a Novartis active pharmaceutical ingredient (Compound B) in comparison with data in healthy adults.
48000 € (NKUA project number 56.90.20391)

Novartis, Switzerland, 2024-2026

Intraluminal characteristics and drug disposition in the upper gastrointestinal lumen after a standard low-calorie low-fat meal with the aim to optimize the biorelevant media testing conditions.
200000 CHF (NKUA project number 56.90.21261)

Novartis, Switzerland, 2026-2027

Characterisation of the duodenal fluid concerning pH, buffer capacity, osmolality, and concentrations of bile salts, phospholipids, and lipids collected from the 24 patients in the 5-12 years old paediatric population via clinical endoscopies
60000€ (NKUA project number 56.90.60029)

Principal Investigator

University of Michigan/Dow Chemical Co., USA (1991 - 1994)

Influence of Methocels® on flow rate, viscosity, and water flux in the gastrointestinal tract

US \$ 16200 (NKUA project number 70/3/849)

Glaxo Research & Development, United Kingdom (1995 - 2003)
Predicting the oral absorption of poorly soluble drugs
British £ 26000 (NKUA project number 70/3/2014)

General Secretariat for Research and Innovation (GSRI): Official website (1999 - 2001)
IVIVCs in the development of extended-release drug products
18.000.000 drachmas (NKUA project number 70/3/4577)

General Secretariat for Research and Innovation (GSRI): Official website (1999 - 2001)
Phytochemical investigation and bioavailability of components from greek olive trees, tomatoes and vineyards
82.500.000 drachmas (NKUA project number 70/3/4942 and 70/3/4912)

PLIVA Pharmaceutical Industry, Zagreb, Croatia (2001-2002)
Predicting oral drug absorption when the rate limiting step is intraluminal release
US \$ 8500 (NKUA project number 70/3/6024)

General Secretariat for Research and Innovation (GSRI): Official website (2002 – 2003)
Development of an oral enabling drug product using pellets and grapefruit components
44000 Ευρώ (NKUA project number 70/3/6217)

Ministry of Education, Religious Affairs and Sports <https://www.minedu.gov.gr/> (2002-2004)
Physicochemical characteristics of luminal contents and their impact on drug release from solid dose units
33369 Euros (NKUA project number 70/3/7221)

AstraZeneca, Moeldal, Sweden (2002-2005)
Drug/Food/Excipient interactions
60000 Euros (NKUA project number 70/3/6268)

Adelco S.A (Athens) (2004)
On the assessment of orally administered calcium products
5000 Euros (NKUA project number 70/3/7330)

Kleva S.A. (Athens) (2004)
On the assessment of oral absorption of diosmine / hesperidine products
5700 Euros (NKUA project number 70/3/7450)

Merck KGaA, Darmstadt, Germany (2004)
EMD 57033 absorption after oral administration to dogs
19000 Euros (NKUA project number 70/3/8073)

Goethe University, Frankfurt, Germany (2004-2005)
Forecasting the performance of dosage forms using biorelevant release tests
5000 Euros (NKUA project number 70/3/7083)

PLIVA Pharmaceutical Industry, Zagreb, Croatia (2004-2005)
In vitro assessment of dissolution characteristics of lipophilic weak bases and salts in the gastrointestinal lumen
7500 Euros (NKUA project number 70/3/7472)

Ministry of Education, Religious Affairs and Sports <https://www.minedu.gov.gr/> (2005-2007)
Predicting oral drug absorption from lipid-based formulations
31978 Ευρώ (ΕΚΠΑ, Κ.Α. 70/3/7967)

AstraZeneca, Moeldal, Sweden (2005-2009)
Characterization of contents of ascending colon in healthy adults and in patients with ulcerative colitis and development of in vitro tests for assessing solubility and release from drug product during residence in the ascending colon
60000 Euros (NKUA project number 70/3/6268)

Capsugel France S.A. (2007)
In vitro assessment of solid lipid formulations: placebos
21500 Euros (NKUA project number 70/3/9286)

Rohm GmbH, Germany (2007)
Felodipine absorption after oral administration to dogs
24000 Euros (NKUA project number 70/3/9292)

Goethe University, Frankfurt, Germany (2008-2009)
Quantification of lipids in the contents of upper small intestine of healthy adults
12800 Euros (NKUA project number 70/3/9630)

GlaxoSmithKline plc, Harlow, UK (2008-2010)
In vivo investigation on the precipitation of weak based in the upper small intestine of healthy adults
118823,51 Euros (NKUA project number 70/3/9555)

Goethe University, Frankfurt, Germany (2010-2012)
In vitro assessment of dispersion of lipid-based formulations
18000 Euros (NKUA project number 70/3/10556)

Merck Sharp & Dohme Corp., USA (2011-2018)
Development of in vitro methods for predicting differences between salts and free acids or free bases of APIs.
Development of in vitro methods for predicting dissolution kinetics of weak bases and their salts under achlorhydric or hypochlorhydric conditions.
Evaluation of precipitation in human intestinal fluids: Focus to weak bases and to solid dispersions
197914 Euros (NKUA project number 56.90.11372).

Innovative Medicines Initiative (IMI) (<http://www.imi.europa.eu>). European Union's Seventh Framework Programme (2012-2017)
Oral Biopharmaceutics Tools (OrBiTo)
488967 Euros (NKUA project number 70/3/11819).

Bayer Pharma AG, Germany (2014-2016)
Evaluation of stability of selected BAYER compounds and of generic compounds in contents of lower intestine and in optimized human fecal material from healthy adults.
96868 Euros (NKUA project number 56.90.12583).

Marie Skłodowska-Curie action, European Union's Horizon 2020 Research and Innovation Programme (2016-2020)
Pharmaceutical Education And Research with Regulatory Links (<http://www.pearl.eu>)
475671 Euros (NKUA project number 70/3/12501).

Merck KGaA, Darmstadt, Germany
Evaluation of the usefulness of BioGIT model in the comparison intraluminal performance of orally administered Merck KGaA active pharmaceutical ingredients formulated as conventional and/or bioenhanced dosage forms (2018-2020)
61000 Euros (NKUA project number 56.90.15463).

Unipharm AEBE, Greece
In vitro investigations on prototype mesalamine formulations aiming at the development of an orally administered modified release product (2020-2021)
36630 Euros (NKUA project number 56.90.17118).

Janssen Pharmaceutica, Belgium
Evaluation of the impact of bacterial activity in the lower intestine on the clinical performance of selected compounds based on data in optimized human fecal material (2020-2021)
46735 Euros (NKUA project number 56.90.17070).

Janssen Pharmaceutica, Belgium
Implementation at Janssen and evaluation of the usefulness of BioGIT model (2020-2021)
15781 Euros (NKUA project number 56.90.17311).

Merz Consumer Care GmbH, Germany (2020-2021)
Clinical effectiveness of a pH increasing test product
42000 Euros (NKUA project number 56.90.15744).

Marie Skłodowska-Curie action, European Union's Horizon 2020 Research and Innovation Programme (2021-2024)

Boosting advanced doctoral training in innovative colon targeting drugs (COLOTAN) (www.colotan-etn.eu)

150487 Euros (NKUA project number 70/3/16917).

Marie Skłodowska-Curie action, European Union's Horizon 2020 Research and Innovation Programme (2021-2024)

A fully integrated, animal-free, end-to-end modelling approach to oral drug product development" (InPharma) (www.inpharma-network.eu)

274083 Euros (NKUA project number 70/3/16971).

Work and Competency Area Taxonomy of Functions & Domains		
FUNCTION / DOMAIN category - EN	Catégorie FONCTION / DOMAINE - FR	Your domain
STATISTICS and general MATHEMATICS	STATISTIQUES et MATHÉMATIQUES générales	
ANALYSIS and INTELLIGENCE	ANALYSE et RENSEIGNEMENT	
KNOWLEDGE MANAGEMENT & ECONOMY	GESTION des CONNAISSANCES & ÉCONOMIE de la CONNAISSANCE	
SCIENCE and RESEARCH	SCIENCE et RECHERCHE	
INNOVATION and CREATIVITY	INNOVATION et CRÉATIVITÉ	
CLIMATE, ENVIRONMENT and NATURAL RESOURCES	CLIMAT, ENVIRONNEMENT et RESSOURCES NATURELLES	
AGRICULTURE	AGRICULTURE	
FORESTRY	SYLVICULTURE	
FISHERY and MARITIME AFFAIRS	PÊCHE et AFFAIRES MARITIMES	
ENTERPRISE and MARKETS	ENTREPRISES et MARCHÉS	
COMMERCE (general)	COMMERCE (général)	
COMPETITION and CONSUMERS	CONCURRENCE et CONSOMMATEURS	
TRADE	COMMERCE	
TAXATION and CUSTOMS	FISCALITÉ et DOUANE	
ECONOMICS	ÉCONOMIE	
FINANCIAL INSTRUMENTS and INSTITUTIONS, incl BANKING	INSTRUMENTS FINANCIERS et INSTITUTIONS FINANCIÈRES, y compris les BANQUES	
BUDGET, FINANCE, CONTRACTS and ACCOUNTING	BUDGET, FINANCES, CONTRATS et COMPTABILITÉ	
POLICY	POLITIQUE	
LAW	DROIT	
LAW ENFORCEMENT	APPLICATION du DROIT	
LEGAL OFFENSE, CRIMINOLOGY and FORENSICS	INFRACTIONS à la LOI, CRIMINOLOGIE et SCIENCES FORENSIQUES	
ANTI-FRAUD	LUTTE contre la FRAUDE	
INVESTIGATION, COMPLIANCE and INFRINGEMENT HANDLING	ENQUÊTES, VÉRIFICATION de CONFORMITÉ et TRAITEMENT des INFRACTIONS	
AUDIT, CONTROL and INSPECTION	AUDIT, CONTRÔLE et INSPECTION	
EVALUATION and QUALITY MANAGEMENT	ÉVALUATION et GESTION de la QUALITÉ	
PROGRAM / PROCESS / PROJECT MANAGEMENT	GESTION de PROJETS, PROGRAMMES et PROCESSUS	
OPERATIONAL and ADMINISTRATIVE SUPPORT and RESOURCES	SUPPORT et RESSOURCES OPÉRATIONNELS et ADMINISTRATIFS	
LOGISTIC SUPPORT	SUPPORT LOGISTIQUE	
TECHNICAL and LABORATORY WORK	TRAVAUX TECHNIQUES et TRAVAUX en LABORATOIRE	
TECHNOLOGIES and ENGINEERING in SCIENCE and INDUSTRY	TECHNOLOGIES et INGÉNIERIE dans les SCIENCES et l'INDUSTRIE	
ENERGY POLICIES and TECHNOLOGIES	POLITIQUES de l'ÉNERGIE et TECHNOLOGIES	
TRANSPORT (incl logistics)	TRANSPORT (y compris logistique)	
BUILDINGS and SUPPLIES (incl logistics)	BÂTIMENTS et FOURNITURES (y compris logistique)	
SAFETY, SECURITY and CRISIS MANAGEMENT	SÉCURITÉ, SÛRETÉ et GESTION de CRISE	
HEALTH	SANTÉ	
EMPLOYMENT (EU/national/regional level)	EMPLOI (UE/national/régional)	
LABOUR LAW	DROIT du TRAVAIL	
HUMAN RESOURCE MANAGEMENT	GESTION des RESSOURCES HUMAINES	
EDUCATION and TRAINING (general)	ÉDUCATION et FORMATION (général)	
CULTURE, HUMANITIES, PHILOSOPHY and HISTORY	CULTURE, SCIENCES HUMAINES, PHILOSOPHIE et HISTOIRE	
LANGUAGES and LINGUISTICS	LANGUES et LINGUISTIQUE	
MULTILINGUAL and TERMINOLOGY RESOURCES	RESSOURCES MULTILINGUES et TERMINOLOGIQUES	
CLASSIFICATION, STANDARDS and NOMENCLATURES	CLASSIFICATION, NORMES et NOMENCLATURES	
INFORMATION and DOCUMENT MANAGEMENT	INFORMATION et GESTION des DOCUMENTS	
COMMUNICATION and PUBLICATION	COMMUNICATION et PUBLICATION	
TELECOMMUNICATION and TELEPHONY	TÉLÉCOMMUNICATIONS et TÉLÉPHONIE	
INFORMATION and COMMUNICATION TECHNOLOGIES	TECHNOLOGIES de l'INFORMATION et de la COMMUNICATION	
IT TOOLS for SPECIFIC APPLICATION AREAS	OUTILS INFORMATIQUES pour des DOMAINES d'APPLICATION SPÉCIFIQUES	
(APPLIED) COMPUTER SCIENCE	INFORMATIQUE (APPLIQUÉE)	
INTER-INSTITUTIONAL RELATIONS	RELATIONS INTERINSTITUTIONNELLES	
JUSTICE and HUMAN/CIVIL RIGHTS	JUSTICE et DROITS HUMAINS/CIVILS	
SOCIAL SCIENCES and POLICIES	SCIENCES et POLITIQUES SOCIALES	
HUMAN GEOGRAPHY	GÉOGRAPHIE HUMAINE	
COHESION POLICY (EU/national level)	POLITIQUE de COHÉSION (UE/national/régional)	
REGIONAL POLICY (EU/national level)	POLITIQUE RÉGIONALE (UE/national/régional)	
DEMOGRAPHY and MIGRATION	DÉMOGRAPHIE et MIGRATION	
EXTERNAL RELATIONS	RELATIONS EXTÉRIEURES	